Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02135536 · ClinicalTrials.gov registry record · Phase 2
Phase 2b Study of NGM282 Extended Treatment in Patients With Primary Biliary Cirrhosis
A Phase 2 study of Primary Biliary Cirrhosis, sponsored by NGM Biopharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 36
- Enrollment target
- 17
- Study locations
NCT02135536: Completed Phase 2 study of Primary Biliary Cirrhosis, sponsored by NGM Biopharmaceuticals.
NCT02135536 is a Phase 2 study of Primary Biliary Cirrhosis that has completed, run by NGM Biopharmaceuticals. The registered enrollment target is 36 participants, below the 1,437-participant average among 7 other Primary Biliary Cirrhosis trials with a reported enrollment target (97% lower). The trial reports 17 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02135536, a Phase 2 study of Primary Biliary Cirrhosis, has completed, sponsored by NGM Biopharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 36 participants
- Enrollment target
- 17
- Study locations
Study Summary
The purpose of this study is to determine the safety, tolerability, and activity of extended treatment with NGM282 in patients with Primary Biliary Cirrhosis.
Conditions Studied
Interventions
- BIOLOGICAL NGM282
Study Locations (17)
New South Wales
- NGM Clinical Study Site 602 - Sydney
- NGM Clinical Study Site 606 - Sydney
- NGM Clinical Study Site 609 - Sydney
- NGM Clinical Study Site 611 - Sydney
Texas
- NGM Clinical Study Site 102 - Dallas
- NGM Clinical Study Site 113 - San Antonio
South Australia
- NGM Clinical Study Site 607 - Adelaide
- NGM Clinical Study Site 608 - Adelaide
Victoria
- NGM Clinical Study Site 601 - Melbourne
- NGM Clinical Study Site 613 - Melbourne
Other
- NGM Clinical Study Site 401 - Auckland
- NGM Clinical Study Site 402 - Christchurch
Arizona
- NGM Clinical Study Site 103 - Phoenix
California
- NGM Clinical Study Site 108 - Coronado
Michigan
- NGM Clinical Study Site 101 - Detroit
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2014-05 |
| Est. Completion | 2016-02 |
| Phase | Phase 2 |
What the finished NCT02135536 record still lists
NCT02135536 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 36 participants, a relatively small participant target, below the 1,437-participant average among 7 other Primary Biliary Cirrhosis trials with a reported enrollment target (97% lower).
The record links to 1 condition, with Primary Biliary Cirrhosis appearing as the primary indexed condition, and to 1 intervention - of which NGM282 is the first listed.
NCT02135536 lists 17 locations in 10 states (New South Wales, Texas, South Australia).
Frequently Asked Questions
What is clinical trial NCT02135536 about?
NCT02135536 is a clinical study titled "Phase 2b Study of NGM282 Extended Treatment in Patients With Primary Biliary Cirrhosis". The purpose of this study is to determine the safety, tolerability, and activity of extended treatment with NGM282 in patients with Primary Biliary Cirrhosis.
What is the current status of trial NCT02135536?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 36 participants. The study started on 2014-05. Estimated completion is 2016-02.
What conditions does trial NCT02135536 study?
This clinical trial studies the following conditions: Primary Biliary Cirrhosis.
What interventions are being tested in trial NCT02135536?
The interventions under investigation include: NGM282 (BIOLOGICAL).
Who is sponsoring clinical trial NCT02135536?
This trial is sponsored by NGM Biopharmaceuticals, which has 18 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02135536 being conducted?
This trial has 17 study locations across Arizona, California, Michigan, North Carolina, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Primary Biliary Cirrhosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase 2 Study to Evaluate LUM001 in Combination With Ursodeoxycholic Acid in Patients With Primary Biliary Cirrhosis
COMPLETED · Phase 2
-
Study to Evaluate Safety, Tolerability and Efficacy of Saroglitazar Mg in Patients With Primary Biliary Cholangitis
COMPLETED · Phase 2
-
Use of Fenofibrate for Primary Biliary Cirrhosis
COMPLETED · Phase 2
-
Biobank for Cholestatic Liver Diseases.
RECRUITING
-
Study of Seladelpar in Participants With Primary Biliary Cholangitis (PBC)
ACTIVE NOT RECRUITING · Phase 3
-
Study of Elafibranor in Patients With Primary Biliary Cholangitis (PBC)
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00929006 · 36 participants · Early Phase 1
Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism
- NCT01891318 · 36 participants · Phase 1
Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study
- NCT02291848 · 36 participants · Phase 1
Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma
- NCT02366819 · 36 participants · Phase 4
Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia